Reports
Reports
Sale
The global meningococcal vaccines market stood at 172 million doses in 2020. The global meningococcal vaccines market is expected to grow at a healthy pace in the forecast period of 2024-2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market growth of meningococcal vaccines is being driven by the rising prevalence of various types of bacteria that trigger meningococcal meningitis. The most common among them are A, B, C, W, Y, and type X that was lately tracked in Africa. This is aiding the market growth of meningococcal vaccines as the demand for effective meningococcal vaccines is on the rise over the forecast period. The market is further being propelled by the extremely unpredictable dissemination of this bacteria and fluctuating occurrences of the disease over time and across different age groups and geographies, which has resulted in a considerable increase in the frequency of clinical programmes for the development of efficient meningococcal vaccines worldwide. Moreover, several ongoing clinical programmes for the development of meningococcal vaccines at varying stages is further facilitating the market growth globally.
Meningococcal meningitis is a rare and potentially disturbing bacterial infection that affects the brain. Even after the advances in the medical field, the disease has the potential to take the life of the host in a relatively lesser timespan. Meningococcal vaccines are produced as the prevention of meningococcal meningitis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of type, the market is divided into:
Based on age group, the industry can be segmented into:
By distribution channel, the industry is categorised into:
These segments are further divided on the basis of type. Institutional sales are divided into hospitals, community clinics, and public health agencies, whereas retail sales are divided into retail pharmacy and online, among others.
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market growth of meningococcal vaccines is being driven by the rising initiatives like National Immunization Programs (NIPs) by the governments and supported by private non-profit organisations for the development of meningococcal vaccines. Further, the addition of meningococcal vaccines to NIPs with the motive to ascertain vaccine supply affordability and sustainability in public and private sectors has been generating an abundance of opportunities for the manufacturers.
The report gives a detailed analysis of the following key players in the global meningococcal vaccines market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Age Group |
|
Breakup by Brand |
|
Breakup by End User |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Meningococcal Vaccines Market Overview
3.1 Global Meningococcal Vaccines Market Historical Value (2017-2023)
3.2 Global Meningococcal Vaccines Market Forecast Value (2024-2032)
4 Global Meningococcal Vaccines Market Landscape
4.1 Global Meningococcal Vaccines Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Meningococcal Vaccines Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by End User
4.2.3 Analysis by Major Regions
5 Global Meningococcal Vaccines Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Meningococcal Vaccines Market Segmentation
6.1 Global Meningococcal Vaccines Market by Type
6.1.1 Market Overview
6.1.2 Mono Vaccines
6.1.3 Combination Vaccines
6.2 Global Meningococcal Vaccines Market by Age Group
6.2.1 Market Overview
6.2.2 Infants
6.2.3 Childrens
6.2.4 Adults
6.3 Global Meningococcal Vaccines Market by Brand
6.3.1 Market Overview
6.3.2 Menactra
6.3.3 Menveo
6.3.4 Nimenrix
6.3.5 Trumenba
6.3.6 Bexsero
6.3.7 Others
6.4 Global Meningococcal Vaccines Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.4.4 Specialty Clinics
6.4.5 Others
6.5 Global Meningococcal Vaccines Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Online Pharmacy
6.5.4 Retail Pharmacy
6.5.5 Others
6.6 Global Meningococcal Vaccines Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Meningococcal Vaccines Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Meningococcal Vaccines Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Meningococcal Vaccines Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Meningococcal Vaccines Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Meningococcal Vaccines Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Johnson & Johnson Private Limited
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Mylan N.V.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Sun Pharmaceutical Industries Limited
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sanofi S.A.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Merck & Co., Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 GSK plc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 AbbVie Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Fresenius Kabi AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Amneal Pharmaceuticals LLC.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Pfizer Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Serum Institute of India Pvt. Ltd.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Incepta Pharmaceuticals Ltd.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Walvax Biotechnology Co., Ltd.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Bio-Manguinhos
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Global Meningococcal Vaccines Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2020, the global meningococcal vaccines market attained 172 million doses.
The major drivers of the industry, such as rising disposable incomes, increasing population, rising prevalence of the disease, and increasing demand for effective meningococcal vaccines, are expected to aid the market growth.
The key market trend guiding the growth of the industry includes the rise in the initiatives undertaken by the government.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading types of meningococcal vaccines in the market are polysaccharide vaccine (MPSV4), conjugate vaccine (MCV4), and serogroup B vaccine (MenB-FHpb/MenB-4C).
The major age groups considered in the market report are infants, children, and adults, among others.
The significant distribution channels in the industry are institutional sales and retail sales.
The major players in the industry are Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, and Incepta Vaccine Ltd., among others.
The global meningococcal vaccines market attained 172 million doses in 2020, driven by rising prevalence of urinary incontinence among the growing geriatric population. Aided by the technological advancements, the market is expected to witness a healthy growth in the forecast period of 2024-2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on type, the market is segmented into polysaccharide vaccine (MPSV4), conjugate vaccine (MCV4), and serogroup B vaccine (MenB-FHpb/MenB-4C). By age group, the industry is divided into infants, children, and adults, among others. On the basis of distribution channel, the market is segmented into institutional sales and retail sales. The major regional markets for meningococcal vaccines are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, and Incepta Vaccine Ltd., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.